Lanifibranor
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Fatty Liver Disease (NAFLD)
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
Trial Timeline
Aug 14, 2018 → Jun 1, 2023
NCT ID
NCT03459079About Lanifibranor
Lanifibranor is a phase 2 stage product being developed by Inventiva for Nonalcoholic Fatty Liver Disease (NAFLD). The current trial status is completed. This product is registered under clinical trial identifier NCT03459079. Target conditions include Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM).
What happened to similar drugs?
0 of 6 similar drugs in Nonalcoholic Fatty Liver Disease (NAFLD) were approved
Approved (0) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03459079 | Phase 2 | Completed |
Competing Products
20 competing products in Nonalcoholic Fatty Liver Disease (NAFLD)